Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA-LP Vaccines in Recurrent Adult Glioblastoma
NCT06389591Phase 1Active, not recruiting
- Sponsor
- University of Florida
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pp65 RNA-LPs and pp65-shLAMP DC in glioblastoma (GBM), sponsored by University of Florida. Primary endpoints: Percentage of vaccines meeting release criteria in the DLT window during the first three vaccines up to 20 weeks and Incidence of investigational treatment related toxicities up to 17 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
pp65 RNA-LPspp65-shLAMP DC
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06389591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389591.